TREATMENT PATTERNS IN MEDICAID BENEFICIARIES WITH SCHIZOPHRENIA REACHING STABILIZED MAINTENANCE WITH ONCE-MONTHLY PALIPERIDONE PALMITATE THERAPY

被引：1
|
作者：
Pilon, D. [1 ]
Muser, E. [2 ]
Emond, B. [1 ]
Xiao, Y. [1 ]
Amos, T. [2 ]
Lefebvre, P. [1 ]
Benson, C. [2 ]
机构：
[1] Grp Anal Ltee, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1868
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH82
引用
收藏
页码：A196 / A196
页数：1
相关论文
共 50 条
  • [21] A PRAGMATIC ANALYSIS COMPARING ONCE-MONTHLY PALIPERIDONE PALMITATE VERSUS DAILY ORAL ANTIPSYCHOTIC TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
    Starr, H. L.
    Bossie, C.
    Benson, C.
    Mao, Lian
    Alphs, L.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S334 - S334
  • [22] A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia
    Alphs, Larry
    Mao, Lian
    Starr, H. Lynn
    Benson, Carmela
    SCHIZOPHRENIA RESEARCH, 2016, 170 (2-3) : 259 - 264
  • [23] Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia
    Hargarter, Ludger
    Lahaye, Marjolein
    Cherubin, Pierre
    Lambert, Martin
    Swarz, Marnina
    Joldygulov, Gali
    Vischia, Flavio
    Chomskaya, Veronica
    Bozikas, Vasilis P.
    Tsapakis, Eva-Maria
    Schreiner, Andreas
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2018, 19 : S147 - S157
  • [24] Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
    Hargarter, L.
    Bergmans, P.
    Cherubin, P.
    Keim, S.
    Conca, A.
    Serrano-Blanco, A.
    Bitter, I.
    Bilanakis, N.
    Schreiner, A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) : 1043 - 1053
  • [25] Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
    Shimizu, Hiroko
    Neyens, Martine
    De Meulder, Marc
    Gopal, Srihari
    Tsukamoto, Yuko
    Samtani, Mahesh N.
    Remmerie, Bart
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 224 - 234
  • [26] Impact of once-monthly paliperidone palmitate treatment on hospitalisation risk in patients with schizophrenia switching from oral antipsychotics
    Li, N.
    Zhuo, J.
    Tan, W.
    Turkoz, I.
    Mathews, M.
    Feng, Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S941 - S941
  • [27] A Pragmatic Analysis Comparing Once-monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment in Patients with Schizophrenia
    Alphs, Larry
    Benson, Carmela
    Bossie, Cynthia
    Mao, Lian
    Starr, H. Lynn
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S364 - S365
  • [28] Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Sliwa, Jennifer Kern
    Ma, Yi-Wen
    Alphs, Larry
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2011, 1 (04) : 111 - 124
  • [29] Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
    El Khoury, Antoine C.
    Patel, Charmi
    Mavros, Panagiotis
    Huang, Ahong
    Wang, Li
    Bashyal, Richa
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 3159 - 3170
  • [30] Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
    El Khoury, Antoine C.
    Pilon, Dominic
    Morrison, Laura
    Shak, Nina
    Llaneza, Amanda
    Kim, Edward
    Lefebvre, Patrick
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 176 - 185
12345